Prelude Therapeutics (PRLD) Cash & Current Investments (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Cash & Current Investments data on file, last reported at $144.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 40.23% year-over-year to $144.6 million; the trailing twelve-month figure through Mar 2026 stood at $144.6 million (up 40.23% YoY), and the FY2025 full-year result was $103.2 million, down 25.02% from the prior year.
• Cash & Current Investments advanced to $144.6 million in Q1 2026, from $103.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $270.2 million in Q1 2022 to a low of $55.0 million in Q3 2025.
• A 5-year average of $181.0 million and a median of $183.9 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments plunged 65.14% in 2025 and surged 40.23% in 2026, its largest moves.
• Tracing PRLD's Cash & Current Investments over 5 years: stood at $205.8 million in 2022, then increased by 15.17% to $237.0 million in 2023, then plunged by 41.91% to $137.7 million in 2024, then dropped by 25.02% to $103.2 million in 2025, then soared by 40.1% to $144.6 million in 2026.
• Business Quant data shows PRLD's Cash & Current Investments at $144.6 million in Q1 2026, $103.2 million in Q4 2025, and $55.0 million in Q3 2025.